Amgen's Beating the Market -- Here's Why It's a Buy Now

Jul 1, 2022 · Under a settlement reached in 2017 between AbbVie and Amgen, Amgen has had to sit on its already FDA-approved potential biosimilar blockbuster, Amjevita, for the U.S. market. …

CouponFollow Extension

89%
OFF

Is Amgen Stock A Buy Now? - The Motley Fool

2 weeks from now

Feb 1, 2024 · Amgen's underlying business remains solid and should continue supporting its dividend. The company currently offers a yield of 2.89%, higher than the S&P 500 's average …

fool.com

75%
OFF

Is Amgen Stock A Buy Now? - The Motley Fool

2 weeks from now

Oct 20, 2022 · Shares of Amgen (AMGN-0.75%) have been rising of late after a recent analyst upgrade generated some bullishness around the biotech company. Year to date, the stock is …

fool.com

$3
OFF

Why Amgen Inc. (AMGN) Is The Best Safe Stock To Buy According …

2 weeks from now

Amgen Inc. (NASDAQ:AMGN) is a safe stock to buy and we say that because of its cash flow situation. During the quarter, the company generated $3.3 billion of free cash flow up from …

msn.com

07%
OFF

Amgen: Multiple Strengths, But The Valuation Is A Concern

2 weeks from now

14 hours ago · Despite Amgen's rising share price, the dividend yield is still above its 5-year average of 3.07%. The forward yield is now about 3.1% after the recent price gain after …

seekingalpha.com

5%
OFF

Why Amgen (AMGN) Is A Top Momentum Stock For The Long …

2 weeks from now

Jan 14, 2025 · AMGN is a Zacks Rank #3 (Hold) stock, with a Momentum Style Score of B and VGM Score of B. Shares are up 4.5% over the past one week and up 1.4% over the past four …

yahoo.com

5%
OFF

Are Wall Street Analysts Predicting Amgen Stock Will Climb Or Sink?

2 weeks from now

3 days ago · Amgen's shares recovered 1.5% following its Q3 earnings release on Oct. 30 due to the company’s stronger-than-expected adjusted EPS of $5.58. The revenue growth of 23% …

nasdaq.com

$275.00
OFF

Amgen (NASDAQ:AMGN) Given New $275.00 Price Target At Bank …

2 weeks from now

1 day ago · Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, …

marketbeat.com

49%
OFF

Is Amgen Stock Still A Buy After An Unexpected Reveal Of Data?

2 weeks from now

Nov 29, 2024 · Shares of Amgen (AMGN 0.49%) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially …

fool.com

4%
OFF

Vertiv (NYSE:VRT) Trading Up 0.4% - Here's Why - MarketBeat

2 weeks from now

23 hours ago · ORG Partners LLC raised its holdings in Vertiv by 25.1% in the third quarter. ORG Partners LLC now owns 458 shares of the company's stock worth $46,000 after purchasing an …

marketbeat.com

FAQs about Amgen's Beating the Market -- Here's Why It's a Buy Now Coupon?

Should you buy Amgen (AMGN) stock?

While Amgen 's (AMGN -4.16%) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the market's unusually large gain of 35.6%, there's no shortage of reasons to buy its stock. Still, there is a risk that could rain on the biotech's parade a bit over the next couple of years. ...

Why should you buy Amgen (Amgen)?

So it could target two markets, which is why it's another reason to buy the stock. In short, Amgen is a massive biopharma, with dozens of pipeline programs and a huge portfolio of products on the market. In the third quarter alone, its top line was $8.5 billion, and it reported $5.22 in diluted earnings per share (EPS). ...

How has Amgen's share price changed over the past 12 months?

The share price rose about 6% in response and has been trending upward since the start of the year on investor optimism. The share price has gained ~17.8% year-to-date ("YTD") but lost ~4.7% in the past twelve months. Amgen's revenue has gained yearly from 2015 to 2024, except for slight declines in 2017 and 2019. ...

Does the market have faith in Amgen?

It has struggled with stiff competition for some of its products and slow revenue growth. However, the market has faith in Amgen, as evidenced by its rising stock price. Is this faith justified? ...

Is Amgen stock a dirt-cheap buy?

Amgen hasn't been generating a lot of growth lately, but its pipeline could change things. Recently approved Lumakras has the potential to be a blockbuster for the company. Amgen's stock isn't a dirt-cheap buy, but its valuation is in line with that of its peers. ...

Does Amgen have a future?

But there is some hope for Amgen. Last year, it acquired rare diseases-focused Horizon Therapeutics for about $28 billion in cash. Horizon has many exciting pipeline products and a key approved medicine called Tepezza that targets thyroid eye disease. Tepezza has only been approved since January 2020. ...